LSKL, Inhibitor of Thrombospondin (TSP-1)

Cat. No.: HY-P0299

CAS No.: 283609-79-0

Molecular Formula: $C_{21}H_{42}N_6O_5$

Molecular Weight: 458.6

Sequence: Leu-Ser-Lys-Leu-NH2

Sequence Shortening: LSKL-NH2

Target: TGF-β Receptor

Pathway: TGF-beta/Smad

Storage: Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (218.05 mM; Need ultrasonic)

H_2O : 50 mg/mL (109.03 mM; Need ultrasonic)

	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1805 mL	10.9027 mL	21.8055 mL
	5 mM	0.4361 mL	2.1805 mL	4.3611 mL
	10 mM	0.2181 mL	1.0903 mL	2.1805 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 100 mg/mL (218.05 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves

	long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier[1][2].
IC_{50} & Target	TGF-β1[1]
In Vitro	The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling[1]. LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1]
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection
Result:	Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.

CUSTOMER VALIDATION

- J Exp Clin Cancer Res. 2022 Aug 26;41(1):259.
- Cell Death Dis. 2022 Jul 30;13(7):663.
- Environ Pollut. 2020 Apr;259:113915.
- Front Immunol. 2022 Mar 18;13:853894.
- Antioxidants (Basel). 2023 Nov 21, 12(12), 2024.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.

[2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61.

[3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an

experimental model. Br J Surg. 2015 Jun;102(7):813-25.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA